Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine)

16 presentations will examine safety and efficacy of AJOVY and AUSTEDOTEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for two of the company’s neurology portfolio treatments, AJOVY® (fr...

Related Keywords

United States ,Israel ,America ,American ,Yael Ashman ,Denisa Hurtukova ,A Survey Of Patients ,Drug Administration ,Teva Pharmaceuticals ,Teva Pharmaceutical Industries Ltd ,Head Of North America Medical Affairs ,Health Care Resource Utilization ,American Academy Of Neurology ,Baseline Abnormal Involuntary Movement Scale Item ,Teva Pharmaceutical Industries ,American Academy ,Annual Meeting ,North America Medical ,Month Safety ,Pooled Analysis ,Disability Outcomes ,Pooled Results ,Placebo Controlled Phase ,Acute Medication Use ,Migraine Initiating Fremanezumab ,Database Analysis ,Migraine Related Health Care Resource Utilization ,Patients Initiating Fremanezumab ,Health Care Costs ,Patients Suffering With Migraine ,Southern Israel ,Retrospective Database Analysis ,Injection Site Adverse Events With Fremanezumab ,Heart Rate ,Blood Pressure ,Participants Treated With Fremanezumab ,Retrospective Database Study ,Patients With Migraine ,Preventive Treatment ,Different Racial ,Ethnic Subgroups ,Unstructured Electronic Medical Record Data ,Tardive Dyskinesia ,Long Term Deutetrabenazine Treatment ,Patients With Tardive Dyskinesia ,Underlying Psychiatric ,Mood Disorders ,Term Efficacy ,Concomitant Dopamine Receptor Antagonist Use ,Social Aspects ,Patient Lives ,Safety Information ,Adverse Events ,Malignant Syndrome ,Melanin Containing Tissues ,Adverse Reactions ,Prescribing Information ,Pharmaceutical Industries ,Private Securities Litigation Reform Act ,Annual Report ,